Analysts Set MiMedx Group, Inc. (NASDAQ:MDXG) Price Target at $12.00

Shares of MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) have been given a consensus rating of "Buy" by the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $12.00.

A number of research analysts recently weighed in on the stock. StockNews.com lowered shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday. Cantor Fitzgerald restated an "overweight" rating and set a $11.00 price objective on shares of MiMedx Group in a report on Thursday, August 1st. Finally, Craig Hallum decreased their price objective on shares of MiMedx Group from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, August 1st.

MiMedx Group Stock Down 2.0 %

Shares of MDXG traded down $0.15 during trading hours on Tuesday, reaching $7.49. 190,620 shares of the stock traded hands, compared to its average volume of 714,238. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The stock has a fifty day simple moving average of $6.14 and a 200 day simple moving average of $6.72. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $9.27. The company has a market cap of $1.10 billion, a price-to-earnings ratio of 13.93 and a beta of 1.94.

Hedge Funds Weigh In On MiMedx Group

Large investors have recently modified their holdings of the business. Caxton Associates LP purchased a new position in shares of MiMedx Group in the first quarter worth about $1,018,000. Victory Capital Management Inc. increased its stake in shares of MiMedx Group by 909.0% in the second quarter. Victory Capital Management Inc. now owns 138,449 shares of the company's stock worth $959,000 after purchasing an additional 124,727 shares in the last quarter. Isthmus Partners LLC grew its stake in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company's stock valued at $27,000 after acquiring an additional 91,714 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock valued at $6,074,000 after acquiring an additional 770,744 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in MiMedx Group by 13.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company's stock valued at $254,000 after acquiring an additional 3,806 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.